Search Results

AltPep Corporation today announced that Soon Hyouk Lee has assumed the position of Chief Business Officer of AltPep.

AltPep Corporation announced that the peer-reviewed Nature journal Scientific Reports has published new results from the Company’s evaluation of its novel SOBA-AD blood test, aimed at detecting Alzheimer’s disease.

AltPep Corporation announced the appointment of Steven E. Kahn, M.B., Ch.B. to its Advisory Board.

AltPep Corporation today announced the completion of a $52.9 million Series B financing round.

AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the appointment of three new Advisory Board members: Paul Aisen, M.D., Sam Gandy, M.D., Ph.D., and Charlie Glabe, Ph.D.

AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, announced that accomplished executive Nancy Hill has assumed the newly created role of Chief Product Officer.

AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the U.S. Food and Drug Administration (FDA) granted the company Breakthrough Device designation for its SOBA-AD diagnostic in development for Alzheimer’s disease (AD).

AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that this week the Proceedings of the National Academy of Sciences (PNAS) will publish results of a groundbreaking study demonstrating a customized, synthetic peptide’s ability to selectively detect Alzheimer’s disease.

Seattle startup AltPep targets amyloid deposits to treat Alzheimer’s Disease.